Human medicines European public assessment report (EPAR): Pomalidomide Accord, pomalidomide, Date of authorisation: 26/07/2024, Status: Authorised

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Lenvima, lenvatinib, Date of authorisation: 28/05/2015, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Trumenba, meningococcal group b vaccine (recombinant, adsorbed), Date of authorisation: 24/05/2017, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Kerendia, finerenone, Date of authorisation: 16/02/2022, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Roctavian, Valoctocogene roxaparvovec, Date of authorisation: 24/08/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Inflectra, infliximab, Date of authorisation: 10/09/2013, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Vemlidy, tenofovir alafenamide, Date of authorisation: 09/01/2017, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Minjuvi, tafasitamab, Date of authorisation: 26/08/2021, Revision: 6, Status: Authorised

Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (18 September 2024)